Clinical Assessment of Bortezomib for Multiple Myeloma in Comparison with Thalidomide
Purpose: We studied the efficacy and safety of bortezomib (BOR) for treatment of multiple myeloma in comparison with thalidomide (THAL) by reference to adverse events, and searched for laboratory markers that could be used for prognostication of patients. Methods: Biochemical data of patients rece...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2011-02-01
|
| Series: | Journal of Pharmacy & Pharmaceutical Sciences |
| Online Access: | https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/8892 |
| _version_ | 1797712042083221504 |
|---|---|
| author | Mitsutoshi Satoh Rieko Oguro Chigusa Yamanaka Katsutoshi Takada Yasuhiro Matsuura Toyomi Akiba Nobuyuki Aotsuka Yoshihiro Tani Hisashi Wakita |
| author_facet | Mitsutoshi Satoh Rieko Oguro Chigusa Yamanaka Katsutoshi Takada Yasuhiro Matsuura Toyomi Akiba Nobuyuki Aotsuka Yoshihiro Tani Hisashi Wakita |
| author_sort | Mitsutoshi Satoh |
| collection | DOAJ |
| description | Purpose: We studied the efficacy and safety of bortezomib (BOR) for treatment of multiple myeloma in comparison with thalidomide (THAL) by reference to adverse events, and searched for laboratory markers that could be used for prognostication of patients.
Methods: Biochemical data of patients receiving BOR and THAL for treatment of multiple myeloma at the Japanese Red Cross Narita Hospital were investigated retrospectively, after obtaining Institutional Review Board approval. Judgment of curative effects complied with the effects criteria of the International Myeloma Working Group (IMWG) [1].
Results: BOR showed a higher rate of effectiveness than THAL for refractory multiple myeloma, and its effects were rapid. BOR treatment prolonged the survival time of THAL-resistant patients. The efficacy of BOR was unrelated to patient age, the number of previous therapeutic regimens, or the disease period. After medication with BOR, patients in whom it had been effective tended to show an increase of the serum alkaline phosphatase (ALP) level. Thrombocytopenia (86.2%) and leucopenia (69.0%) were observed at high frequencies, but no previously unreported adverse events or fatalities were associated with BOR therapy.
Conclusion: It is suggested that BOR has therapeutic efficacy for multiple myeloma as a first-line medical treatment and/or for patients with THAL resistance, and can improve prognosis and survival. Since serum ALP elevation was observed in many patients for whom BOR was effective, this may be a predictor of BOR efficacy. |
| first_indexed | 2024-03-12T07:15:57Z |
| format | Article |
| id | doaj.art-2464c1c6e0ca4f5b9f9f456e97a71f5c |
| institution | Directory Open Access Journal |
| issn | 1482-1826 |
| language | English |
| last_indexed | 2024-03-12T07:15:57Z |
| publishDate | 2011-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Journal of Pharmacy & Pharmaceutical Sciences |
| spelling | doaj.art-2464c1c6e0ca4f5b9f9f456e97a71f5c2023-09-02T22:46:19ZengFrontiers Media S.A.Journal of Pharmacy & Pharmaceutical Sciences1482-18262011-02-0114110.18433/J3VP44Clinical Assessment of Bortezomib for Multiple Myeloma in Comparison with ThalidomideMitsutoshi SatohRieko OguroChigusa YamanakaKatsutoshi TakadaYasuhiro MatsuuraToyomi AkibaNobuyuki AotsukaYoshihiro TaniHisashi WakitaPurpose: We studied the efficacy and safety of bortezomib (BOR) for treatment of multiple myeloma in comparison with thalidomide (THAL) by reference to adverse events, and searched for laboratory markers that could be used for prognostication of patients. Methods: Biochemical data of patients receiving BOR and THAL for treatment of multiple myeloma at the Japanese Red Cross Narita Hospital were investigated retrospectively, after obtaining Institutional Review Board approval. Judgment of curative effects complied with the effects criteria of the International Myeloma Working Group (IMWG) [1]. Results: BOR showed a higher rate of effectiveness than THAL for refractory multiple myeloma, and its effects were rapid. BOR treatment prolonged the survival time of THAL-resistant patients. The efficacy of BOR was unrelated to patient age, the number of previous therapeutic regimens, or the disease period. After medication with BOR, patients in whom it had been effective tended to show an increase of the serum alkaline phosphatase (ALP) level. Thrombocytopenia (86.2%) and leucopenia (69.0%) were observed at high frequencies, but no previously unreported adverse events or fatalities were associated with BOR therapy. Conclusion: It is suggested that BOR has therapeutic efficacy for multiple myeloma as a first-line medical treatment and/or for patients with THAL resistance, and can improve prognosis and survival. Since serum ALP elevation was observed in many patients for whom BOR was effective, this may be a predictor of BOR efficacy.https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/8892 |
| spellingShingle | Mitsutoshi Satoh Rieko Oguro Chigusa Yamanaka Katsutoshi Takada Yasuhiro Matsuura Toyomi Akiba Nobuyuki Aotsuka Yoshihiro Tani Hisashi Wakita Clinical Assessment of Bortezomib for Multiple Myeloma in Comparison with Thalidomide Journal of Pharmacy & Pharmaceutical Sciences |
| title | Clinical Assessment of Bortezomib for Multiple Myeloma in Comparison with Thalidomide |
| title_full | Clinical Assessment of Bortezomib for Multiple Myeloma in Comparison with Thalidomide |
| title_fullStr | Clinical Assessment of Bortezomib for Multiple Myeloma in Comparison with Thalidomide |
| title_full_unstemmed | Clinical Assessment of Bortezomib for Multiple Myeloma in Comparison with Thalidomide |
| title_short | Clinical Assessment of Bortezomib for Multiple Myeloma in Comparison with Thalidomide |
| title_sort | clinical assessment of bortezomib for multiple myeloma in comparison with thalidomide |
| url | https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/8892 |
| work_keys_str_mv | AT mitsutoshisatoh clinicalassessmentofbortezomibformultiplemyelomaincomparisonwiththalidomide AT riekooguro clinicalassessmentofbortezomibformultiplemyelomaincomparisonwiththalidomide AT chigusayamanaka clinicalassessmentofbortezomibformultiplemyelomaincomparisonwiththalidomide AT katsutoshitakada clinicalassessmentofbortezomibformultiplemyelomaincomparisonwiththalidomide AT yasuhiromatsuura clinicalassessmentofbortezomibformultiplemyelomaincomparisonwiththalidomide AT toyomiakiba clinicalassessmentofbortezomibformultiplemyelomaincomparisonwiththalidomide AT nobuyukiaotsuka clinicalassessmentofbortezomibformultiplemyelomaincomparisonwiththalidomide AT yoshihirotani clinicalassessmentofbortezomibformultiplemyelomaincomparisonwiththalidomide AT hisashiwakita clinicalassessmentofbortezomibformultiplemyelomaincomparisonwiththalidomide |